{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T14:31:12Z","timestamp":1771943472460,"version":"3.50.1"},"reference-count":40,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2020,8,2]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Determining the site of origin of a metastatic neuroendocrine tumour (NET) can be challenging and has important prognostic and therapeutic implications. An immunohistochemical (IHC) panel consisting of TTF1, CDX2, PAX8\/PAX6 and Islet1 is often employed. However, there can be a significant IHC overlap among different primary sites. Herein, we sought to determine the utility of including Special AT-rich sequence binding protein-2 (SATB2) in the IHC panel that is used for determining the site of origin of a metastatic NET.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Paraffin tissue microarrays consisting of 137 primary NETs (26 lung, 22 jejunoileal, 8 appendix, 5 stomach, 4 duodenum, 17 rectum and 55 pancreas) were stained for SATB2, in addition to the well-described lineage-associated markers, such as TTF1, CDX2, PAX6 and Islet1. Additionally, a tissue microarray consisting of 21 metastatic NETs (1 lung, 1 stomach, 8 jejunoileal and 11 pancreas) was stained for TTF1, CDX2, SATB2 and Islet1. The results were recorded as no staining, weak staining and moderate to strong staining.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All appendiceal NETs and majority (88%) of the rectal NETs were positive for SATB2. All primary foregut NETs (stomach, pancreas, duodenum and lung) were negative for SATB2, except for one pulmonary NET with weak staining. However, among the metastatic tumours, 5 of 11 pancreatic NETs, 1 stomach NET, 1 lung NET and 2 of 8 jejunoileal NETs showed weak staining. Receiver operating characteristic analysis incorporating sensitivity and specificity data of IHC panel, considering moderate to strong staining as truly positive cases, showed that inclusion of SATB2 to the previously described NET IHC panel outperformed the panel without SATB2, raising the specificity for pancreaticoduodenal NETs from 81.2% to 100%, with a positive predictive value (PPV) of 100% and negative predictive value (NPV) of 82.22% (p&lt;0.0001); for appendiceal NETs the specificity changed from 99.1% to 98.5% and sensitivity increased from 11.8% to 80%, with a PPV and NPV of 66.67% and 99.26%, respectively (p&lt;0.0001); and for rectal NETs the specificity increased from 97.6% to 99.3% and sensitivity raised from 7.1% to 66.7%, with a PPV and NPV of 80% and 98.53%, respectively (p&lt;0.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SATB2 stain is useful in differentiatingIslet1\/PAX6 positive pancreatic and rectal NETs, as rectal NETs are typically moderately to strongly positive for SATB2 and pancreatic NETs are usually negative or weakly positive for SATB2. Moderate to strong staining for SATB2 is suggestive of an appendiceal or a rectal primary. SATB2 may complement the panel of CDX2, TTF1 and Islet1 in determining the site of origin of an NET in a metastatic setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2020-206645","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T17:22:49Z","timestamp":1600190569000},"page":"582-588","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours"],"prefix":"10.1136","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5094-2424","authenticated-orcid":false,"given":"Sambit Kumar","family":"Mohanty","sequence":"first","affiliation":[{"name":"Pathology and Laboratory Medicine, Advanced Medical Research Institute, Bhubaneswar, Odisha, India"},{"name":"Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Advanced Medical Research Institute, Bhubaneswar, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Advanced Medical Research Institute, Bhubaneswar, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fai","family":"Chuang","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Kim","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector","family":"Lugo","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer Al","family":"Diffalha","sequence":"additional","affiliation":[{"name":"Pathology, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariza","family":"Peralta-Venturina","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie","family":"Balzer","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepti","family":"Dhall","sequence":"additional","affiliation":[{"name":"Pathology, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"2025120518452374000_74.9.582.1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.semdp.2015.09.013","article-title":"Problems with the diagnosis of metastatic neuroendocrine neoplasms. which diagnostic criteria should we use to determine tumor origin and help guide therapy?","volume":"32","author":"Koo","year":"2015","journal-title":"Semin Diagn Pathol"},{"key":"2025120518452374000_74.9.582.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70410-2"},{"key":"2025120518452374000_74.9.582.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2018.04.008"},{"key":"2025120518452374000_74.9.582.4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.5858\/arpa.2015-0314-RA","article-title":"Recent updates on neuroendocrine tumors from the gastrointestinal and pancreatobiliary tracts","volume":"140","author":"Kim","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"2025120518452374000_74.9.582.5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.anndiagpath.2017.04.005","article-title":"Recent updates on grading and classification of neuroendocrine tumors","volume":"29","author":"Kim","year":"2017","journal-title":"Ann Diagn Pathol"},{"key":"2025120518452374000_74.9.582.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0110-y"},{"key":"2025120518452374000_74.9.582.7","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0b013e3182a2dc67"},{"key":"2025120518452374000_74.9.582.8","doi-asserted-by":"publisher","DOI":"10.1159\/000335597"},{"key":"2025120518452374000_74.9.582.9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/modpathol.2012.34","article-title":"Value of islet 1 and Pax8 in identifying metastatic neuroendocrine tumors of pancreatic origin","volume":"25","author":"Koo","year":"2012","journal-title":"Mod Pathol"},{"key":"2025120518452374000_74.9.582.10","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000131531.75602.b9"},{"key":"2025120518452374000_74.9.582.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2004.02.016"},{"key":"2025120518452374000_74.9.582.12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1385\/EP:15:3:247","article-title":"Cdx2 as a marker for neuroendocrine tumors of unknown primary sites","volume":"15","author":"Erickson","year":"2004","journal-title":"Endocr Pathol"},{"key":"2025120518452374000_74.9.582.13","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.5858\/2006-130-1522-EOTITF","article-title":"Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin","volume":"130","author":"Jaffee","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"2025120518452374000_74.9.582.14","doi-asserted-by":"publisher","DOI":"10.1097\/01.pai.0000210416.53493.0f"},{"key":"2025120518452374000_74.9.582.15","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200106000-00015"},{"key":"2025120518452374000_74.9.582.16","doi-asserted-by":"publisher","DOI":"10.1309\/UKN6PVRKXHG422DA"},{"key":"2025120518452374000_74.9.582.17","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31818d7d8b"},{"key":"2025120518452374000_74.9.582.18","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb56f"},{"key":"2025120518452374000_74.9.582.19","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000164073.08093.5d"},{"key":"2025120518452374000_74.9.582.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2006.07.033"},{"key":"2025120518452374000_74.9.582.21","doi-asserted-by":"publisher","DOI":"10.1007\/BF01658532"},{"key":"2025120518452374000_74.9.582.22","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb2a5"},{"key":"2025120518452374000_74.9.582.23","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb168"},{"key":"2025120518452374000_74.9.582.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9020"},{"key":"2025120518452374000_74.9.582.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61742-X"},{"key":"2025120518452374000_74.9.582.26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12022-014-9346-3","article-title":"Comparison of Pax6 and Pax8 as immunohistochemical markers for pancreatic neuroendocrine tumors","volume":"26","author":"Lai","year":"2015","journal-title":"Endocr Pathol"},{"key":"2025120518452374000_74.9.582.27","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPWW2URZ9JKQJU"},{"key":"2025120518452374000_74.9.582.28","first-page":"7072","article-title":"Satb2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors","volume":"8","author":"Li","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"2025120518452374000_74.9.582.29","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31821c3dae"},{"key":"2025120518452374000_74.9.582.30","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0681-12.2012"},{"key":"2025120518452374000_74.9.582.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.05.012"},{"key":"2025120518452374000_74.9.582.32","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1153003"},{"key":"2025120518452374000_74.9.582.33","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddg248"},{"key":"2025120518452374000_74.9.582.34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/his.13943","article-title":"SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas","volume":"76","author":"Bellizzi","year":"2020","journal-title":"Histopathology"},{"key":"2025120518452374000_74.9.582.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152448","article-title":"Value of SATB2, Isl1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors","volume":"215","author":"Zhao","year":"2019","journal-title":"Pathol Res Pract"},{"key":"2025120518452374000_74.9.582.36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/his.14012","article-title":"Satb2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours","volume":"76","author":"Hoskoppal","year":"2020","journal-title":"Histopathology"},{"key":"2025120518452374000_74.9.582.37","unstructured":"Beasley MB TF , Hasleton PS . Carcinoid tumor. In: Travis WD BE , Muller- Hermelink HK , Harris CC , eds. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press, 2004: 59\u201362."},{"key":"2025120518452374000_74.9.582.38","unstructured":"Rindi G , Bosman FT . The Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT , Hruban RH , Theise ND , eds. Who classification of tumors of the digestive system. Lyon: IARC Press, 2010: 13\u201314."},{"key":"2025120518452374000_74.9.582.39","doi-asserted-by":"publisher","DOI":"10.2307\/2531595"},{"key":"2025120518452374000_74.9.582.40","first-page":"1639","article-title":"Immunohistochemical and mRNA Analysis of SATB2 Expression in Neuroendocrine Neoplasms of Pancreas and Midgut (Abstract #1749)","volume":"33","author":"De Michele","year":"2020","journal-title":"Mod Pathol"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2020-206645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T02:45:35Z","timestamp":1764989135000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2020-206645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,8,19]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/jclinpath-2020-206645"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2020-206645","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]}}}